Damora Therapeutics, Inc. Ordinary Shares
DMRA
26 hedge funds and large institutions have $57.4M invested in Damora Therapeutics, Inc. Ordinary Shares in 2021 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 3 increasing their positions, 8 reducing their positions, and 5 closing their positions.
140% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 5
37% more funds holding
Funds holding: 19 → 26 (+7)
0.37% less ownership
Funds ownership: 2.17% → 1.8% (-0.37%)
31% less capital invested
Capital invested by funds: $82.9M → $57.4M (-$25.6M)
63% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$1.13M |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$407K |
| 3 |
Wells Fargo
San Francisco,
California
|
+$245K |
| 4 |
Renaissance Technologies
New York
|
+$216K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$166K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
-$5.31M |
| 2 |
BlackRock
New York
|
-$2.9M |
| 3 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$2.72M |
| 4 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$2.16M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$810K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Citigroup
New York
| $1K | +$1.36K | +10 | New |
|
|
SFM
27
Sphera Funds Management
Tel Aviv,
Israel
| – | -$2.72M | -17,921 | Closed |
|
|
28
Fidelity Investments
Boston,
Massachusetts
| – | -$810K | -5,333 | Closed |
|
29
Millennium Management
New York
| – | -$503K | -3,314 | Closed |
|
|
WMSA
30
Weiss Multi-Strategy Advisers
New York
| – | -$98K | -646 | Closed |
|
31
Goldman Sachs
New York
| – | -$81K | -536 | Closed |
|
DMRA Hedge Fund Activity: Q2 2021 in Review
26 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Damora Therapeutics, Inc. Ordinary Shares (DMRA) for Q2 2021, worth a combined $57.4M — down 31% from $82.9M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new DMRA positions and 5 closed out — a net gain of 7 holders — while 3 added to existing stakes and 8 trimmed.
The largest buyer was Bridgeway Capital Management, opening a new position worth an estimated $1.13M. The largest seller was Soleus Capital Management, cutting an estimated $5.31M.
- 26 institutional investors held Damora Therapeutics, Inc. Ordinary Shares (DMRA) as of Q2 2021, up from 19 in Q1 2021.
- Funds reported $57.4M of Damora Therapeutics, Inc. Ordinary Shares stock for Q2 2021, down 31% quarter-over-quarter.
- 12 funds opened new Damora Therapeutics, Inc. Ordinary Shares positions in Q2 2021 and 5 closed out, a net change of +7 holders.
- The largest Damora Therapeutics, Inc. Ordinary Shares buyer in Q2 2021 was Bridgeway Capital Management, an estimated $1.13M added.
- The largest Damora Therapeutics, Inc. Ordinary Shares seller in Q2 2021 was Soleus Capital Management, an estimated $5.31M sold.
Based on aggregated 13F filings for Q2 2021.